Business Description
Mabpharm Ltd
ISIN : KYG5780F1046
Total Employee Number:
389Compare
Compare
Traded in other countries / regions
02181.Hong Kong IPO Date
2019-05-31Description
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | 0.14 | |||||
Debt-to-Equity | 2.08 | |||||
Debt-to-EBITDA | 4.4 | |||||
Interest Coverage | 1.21 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | -0.14 | |||||
Beneish M-Score | -0.32 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 125.9 | |||||
3-Year FCF Growth Rate | 50.3 | |||||
3-Year Book Growth Rate | -27.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.39 | |||||
9-Day RSI | 54.95 | |||||
14-Day RSI | 53.25 | |||||
3-1 Month Momentum % | -10.99 | |||||
6-1 Month Momentum % | -20.59 | |||||
12-1 Month Momentum % | -50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.81 | |||||
Quick Ratio | 0.56 | |||||
Cash Ratio | 0.2 | |||||
Days Inventory | 654.92 | |||||
Days Sales Outstanding | 73.45 | |||||
Days Payable | 118.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.79 | |||||
Operating Margin % | 2.02 | |||||
Net Margin % | 8.88 | |||||
EBITDA Margin % | 11.56 | |||||
FCF Margin % | -3.57 | |||||
OCF Margin % | 12.49 | |||||
ROE % | 50.23 | |||||
ROA % | 5.37 | |||||
ROIC % | 1.38 | |||||
3-Year ROIIC % | 88.27 | |||||
ROC (Joel Greenblatt) % | 2.38 | |||||
ROCE % | 2.26 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 39.55 | |||||
PE Ratio without NRI | 39.55 | |||||
Price-to-Owner-Earnings | 87 | |||||
PS Ratio | 2.52 | |||||
PB Ratio | 10.88 | |||||
Price-to-Tangible-Book | 21.75 | |||||
Price-to-Operating-Cash-Flow | 20.71 | |||||
EV-to-EBIT | 124.52 | |||||
EV-to-EBITDA | 24.92 | |||||
EV-to-Revenue | 2.88 | |||||
EV-to-FCF | -80.6 | |||||
Price-to-GF-Value | 0.22 | |||||
Price-to-Graham-Number | 7.25 | |||||
Earnings Yield (Greenblatt) % | 0.8 | |||||
FCF Yield % | -1.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mabpharm Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 710.559 | ||
| EPS (TTM) (HK$) | 0.011 | ||
| Beta | 0.7201 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | 65.2 | ||
| 14-Day RSI | 53.25 | ||
| 14-Day ATR (HK$) | 0.014388 | ||
| 20-Day SMA (HK$) | 0.4095 | ||
| 12-1 Month Momentum % | -50 | ||
| 52-Week Range (HK$) | 0.31 - 0.87 | ||
| Shares Outstanding (Mil) | 4,124.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mabpharm Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mabpharm Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mabpharm Ltd Frequently Asked Questions
What is Mabpharm Ltd(HKSE:02181)'s stock price today?
The current price of HKSE:02181 is HK$0.44. The 52 week high of HKSE:02181 is HK$0.87 and 52 week low is HK$0.31.
When is next earnings date of Mabpharm Ltd(HKSE:02181)?
The next earnings date of Mabpharm Ltd(HKSE:02181) is .
Does Mabpharm Ltd(HKSE:02181) pay dividends? If so, how much?
Mabpharm Ltd(HKSE:02181) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Mabpharm Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers